SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
8-K	Oct 1, 2026	Oct 1, 2026	View filing
4	Oct 1, 2026	Oct 1, 2026	View filing
SC 13G	Sep 1, 2026	Sep 1, 2026	View filing
10-Q	Aug 13, 2026	Aug 13, 2026	View filing
8-K	Aug 13, 2026	Aug 13, 2026	View filing
4	Jun 24, 2026	Jun 24, 2026	View filing
8-K	Jun 23, 2026	Jun 23, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
10-Q	May 14, 2026	May 14, 2026	View filing
8-K	May 14, 2026	May 14, 2026	View filing
DEFA14A	Apr 28, 2026	Apr 28, 2026	View filing
DEF 14A	Apr 28, 2026	Apr 28, 2026	View filing
4	Apr 1, 2026	Apr 1, 2026	View filing
10-K	Mar 31, 2026	Mar 31, 2026	View filing
8-K	Mar 31, 2026	Mar 31, 2026	View filing
8-K	Mar 30, 2026	Mar 30, 2026	View filing
SC 13D/A	Mar 20, 2026	Mar 20, 2026	View filing
4	Mar 20, 2026	Mar 20, 2026	View filing
4	Mar 20, 2026	Mar 20, 2026	View filing
8-K	Feb 23, 2026	Feb 23, 2026	View filing
8-K	Jan 13, 2026	Jan 13, 2026	View filing
SC 13D/A	Jan 6, 2026	Jan 6, 2026	View filing
4	Jan 6, 2026	Jan 6, 2026	View filing
SC 13D/A	Jan 5, 2026	Jan 5, 2026	View filing
4	Jan 5, 2026	Jan 5, 2026	View filing
4	Jan 5, 2026	Jan 5, 2026	View filing
4	Jan 5, 2026	Jan 5, 2026	View filing
4	Jan 5, 2026	Jan 5, 2026	View filing
4	Jan 5, 2026	Jan 5, 2026	View filing
4	Jan 5, 2026	Jan 5, 2026	View filing

About Fortress Biotech, Inc.

Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.

Bay Harbor Islands, FL

78 employees

www.fortressbiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lindsay A. Rosenwald

View full financials